The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1921-1926

  Gruber, Rudolf ^a   Van Haarlem, Leonardus J M ^b   Warnaar, Sven O ^b   Holz, Elena ^c   Riethmüller, Gert ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Amgen Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; EDRECOLOMAB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADVERSE DRUG REACTION; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANAPHYLAXIS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0034032007     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Knox, S. Overview of studies on experimental radioimmunotherapy. Cancer Res., 55 (Suppl.): S5832-S5836, 1995.
2. Lind, P., Lechner, P., and Hausmann, B. Development of human antimouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunoconjug. Radiopharm., 4: 811-818, 1991.
3. Fagerberg, J., Frodin, J. E., Ragnhammar, P., Steinitz, M., Wigzell, H., and Mellstedt, H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (abl). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?. Cancer Immunol. Immunother., 38: 149-159, 1994.
4. Baum, R. P., Niesen, A., Hertel, A., Nancy, A., Hess, H., Donnerstag, B., Sykes, T. R., Sykes, C. J., Suresh, M. R., Noujaim, A. A., and Hor, G. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (Phila.), 73: 1121-1125, 1994.
5. Herlyn, D., Sears, H., Iliopoulos, D., Lubeck, M., Douillard, J. Y., Sindelar, W., Tempero, M., Mellstedt, H., Maher, M., and Koprowski, H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma., 5 (Suppl. 1): S51-S58, 1986.
6. Ma, J., Samuel, J., Kwon, G. S., Noujaim, A. A., and Madiyalakan, R. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol. Immunother., 47: 13-20, 1998.
7. Mojiminiyi, S. A., Shepstone, B. J., and Soper, N. D. "Human antimurine antibodies (HAMA) in vivo complex formation and the outcome of immunoscintigraphy" (Letter). J. Nucl Med., 31: 381-382, 1990.
8. Rettenbacher, L., and Galvan, G. Anaphylactic shock after repeated injection of 99mTc-labeled CEA antibody (in German). Nuklearmedizin, 33: 127-128, 1994.
9. Sakahara, H., Reynolds, J. C., Carrasquillo, J. A., Lora, M. E., Maloney, P. J., Lotze, M. T., Larson, S. M., and Neumann, R. D. In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J. Nucl. Med., 30: 1311-1317, 1989.
10. Herlyn, D., Lubeck, M., Sears, H., and Koprowski, H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J. Immunol. Methods, 85: 27-38, 1985.
11. Koprowsky, H., Herlyn, D., Lubeck, M., DeFreitas, E., and Sears, H. F. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. USA., 81: 216-219, 1984.
12. Frodin, J.-E., Faxas, M.-E., Hagström, B., Lefvert, A.-K., Masucci, G., Nilsson, B., Steinitz, M., Unger, P., and Mellstedt, H. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome - an important antitumoral effector function?. Hybridoma., 10: 421-431, 1991.
13. Herlyn, D., Wettendorff, M., Schmoll, E., Iliopoulos, D., Schedel, I., Dreikhausen, U., Raab, R., Ross, A. H., Jaksche, H., Scriba, M., and Koprowski, H. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc. Natl. Acad. Sci. USA, 84: 8055-8059, 1987.
14. Fagerberg, J., Hjelm, A. L., Ragnhammar, P., Frodin, J. E., Wigzell, H., and Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res., 55: 1824-1827, 1995.
15. Raychaudhuri, S., Saeki, Y., Chen, J. J., Iribe, H., Fuji, H., and Kohler, H. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related response induced by the tumor and by internal image antigens (Ab2β). J. Immunol., 139: 271-278, 1987.
16. Somasundaram, R., Zaloudik, J., Jacob, L., Benden, A., Sperlagh, M., Hart, E., Marks, G., Kane, M., Mastangelo, M., and Herlyn, D. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J. Immunol., 155: 3253-3256, 1995.
17. Herlyn, D., Somasundaram, R., Li, W., and Maruyama, H. Anti-idiotypic cancer vaccines: past and future. Cancer Immunol. Immunother., 43: 65-76, 1996.
18. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenler randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
19. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Picklmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and Group, G. C. A.-A. S. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duckes' C colorectal carcinoma. Lancet., 343: 1177-1183, 1994.
20. Litvinov, S., Velders, M., Bakker, H., Fleuren, G., and Warnaar, S. Ep-CAM. A human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol., 125: 437-446, 1994.
21. Hoffman, T. Anticipating, recognizing, and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti-mouse antibodies, Cancer Res. 50: S1049-S1050, 1990.
22. Khazaeli, M., Conry, R., and LoBuglio, A. Human immune response to monoclonal antibodies. J. Immunother., 15: 42-52, 1994.
23. Conry, R. M., Khazaeli, M. B., and LoBuglio, A. F. Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. Cancer Res., 52: 6979-6982, 1992.
24. Steplewski, Z., Chang, T., Herlyn, M., and Koprowski, H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res., 41; 2723-2727, 1981.
25. Koper, N. P., Thomas, C. M., Massuger, L. F., Segers, M. F., Olthaar, A. J., and Verbeek, A. L. Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography. Clin. Chem. Lab. Med., 36: 23-28, 1998.
26. Sears, H., Herlyn, D., Steplewski, Z., and Koprowski, H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridioma, 5 (Suppl. 1): S109-S115, 1986.
27. Sindelar, W., Maher, M., Herlyn, D., Sears, H., Steplewski, Z., and Koprowski, H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma, 5 (Suppl. 1): S125-S132, 1986.
28. Saleh, M., LoBuglio, A., Wheeler, R., Rogers, K., Haynes, A., Lee, J., and Khazaeli, M. A Phase II trial of murine monoclonal antibody 17-1A and g-IFN - clinical and immunological data. Cancer Immunol. Immunother., 32: 185-190, 1990.
29. LoBuglio, A., Saleh, M., Peterson, L., Wheeler, R., Carrano, R., Huster, W., and Khazaeli, M. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma. 5 (Suppl. 1): S117-S123, 1986.
30. Blottiere, H., Steplewski, Z., Herlyn, D., and Douillard, J. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. Hum. Antib. Hybrid., 2: 16-25, 1991.
31. Douillard, J., Lehur, P., Vignoud, J., Blottiere, H., Maurel, C., Thedrez, P., Kremer, M., and LeMevel, B. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma, 5 (Suppl. 1): S139-S149, 1986.
32. Sears, H., Herlyn, D., Koprowski, H., and Shen, J. Immunotherapy of gastrointestinal malignancies with a murine IgG2A antibody. In: G. Riethmüller, H. Koprowski, S. von Kleist, and K. Munk (eds.), Genes and Antigens in Cancer Cells, Vol. 19, pp. 180-192. Basel: Karger AG, 1984.
33. Gruber, R., Holz, E., and Riethmüller, G. Monoclonal antibodies in cancer therapy. Springer Semin. Immunopathol., 18: 243-251, 1996.
34. Herlyn, D., Steplewski, Z., Herlyn, M., and Koprowski, H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res., 40: 717-721, 1980.
35. Mellstedt, H., Frödin, J. E., Masucci, G., Ragnhammer, P., Fageberg, J., Hjelm, A. L., Shetye, J., Wersall, P., and Osterborg, A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin. Oncol., 1: 462-477, 1991.
36. Riethmüller, G., and Johnson, P. Monoclonal antibodies in the detection and therapy of micromestastatic epithelial cancers. Curr. Opin. Immunol., 4: 647-655, 1992.
37. Riethmüller, G., Schneider-Gädicke, E., and Johnsen, J. P. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol., 5: 732-739, 1993.
38. Shoenfeld, Y., Amital, H., Ferrone, S., and Kennedy, R. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. Int. Arch. Allergy Immmunol., 105: 211-223, 1994.
39. Chattopadhyay, P., Sneed, D., Rosenberg, J., Starkey, J., Robertson, N., Leonard, J., and Raychaudhuri, S. Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies. Cancer Res., 51: 3183-3192, 1991.
40. Cheung, N. K., Cheung, I. Y., Canete, A., Yeh, S. J., Kushner, B., Bonilla, M. A., Heller, G., and Larson, S. M. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res., 54: 2228-2233, 1994.
41. Fagerberg, J., Ragnhammar, P., Liljefors, M., Hjelm, A. L., Mellstedt, H., and Frodin, J. E. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A, Cancer Immunol. Immunother., 42: 81-87, 1996.